Discusses the potential role of multiplex respiratory testing for SARS-CoV-2, influenza virus and RSV, and emerging issues related to highly pathogenic avian influenza virus.
According to the 2023 Canadian Thoracic Society guidelines on pharmacotherapy in patients
with stable COPD, all the following statements are true, EXCEPT for . . .
Study provides insight on the value of a new orally-administered, selective P2X3 receptor antagonist antitussive that is under review by Health Canada.